RESVERATROL LIPID BASED NANOPARTICLES SHOW A PROMISING OUTCOME ON INDUCED NON ALCOHOLIC FATTY LIVER DISEASE
Abdelmalek, D., Abd-Elhamid, B., Abd Ellah, N., Ismail, S. (2023). RESVERATROL LIPID BASED NANOPARTICLES SHOW A PROMISING OUTCOME ON INDUCED NON ALCOHOLIC FATTY LIVER DISEASE. EKB Journal Management System, 46(2), 715-727. doi: 10.21608/bfsa.2023.327652
Dina Adel Abdelmalek; Basma Nagy Abd-Elhamid; Noura Hassan Abd Ellah; Sayed Ismail. "RESVERATROL LIPID BASED NANOPARTICLES SHOW A PROMISING OUTCOME ON INDUCED NON ALCOHOLIC FATTY LIVER DISEASE". EKB Journal Management System, 46, 2, 2023, 715-727. doi: 10.21608/bfsa.2023.327652
Abdelmalek, D., Abd-Elhamid, B., Abd Ellah, N., Ismail, S. (2023). 'RESVERATROL LIPID BASED NANOPARTICLES SHOW A PROMISING OUTCOME ON INDUCED NON ALCOHOLIC FATTY LIVER DISEASE', EKB Journal Management System, 46(2), pp. 715-727. doi: 10.21608/bfsa.2023.327652
Abdelmalek, D., Abd-Elhamid, B., Abd Ellah, N., Ismail, S. RESVERATROL LIPID BASED NANOPARTICLES SHOW A PROMISING OUTCOME ON INDUCED NON ALCOHOLIC FATTY LIVER DISEASE. EKB Journal Management System, 2023; 46(2): 715-727. doi: 10.21608/bfsa.2023.327652

RESVERATROL LIPID BASED NANOPARTICLES SHOW A PROMISING OUTCOME ON INDUCED NON ALCOHOLIC FATTY LIVER DISEASE

Bulletin of Pharmaceutical Sciences Assiut University
Volume 46, Issue 2, December 2023, Page 715-727  XML PDF (1.41 MB)
Document Type: Original Article
DOI: 10.21608/bfsa.2023.327652
View on SCiNiTO View on SCiNiTO
Authors
Dina Adel Abdelmalek email 1; Basma Nagy Abd-Elhamid1; Noura Hassan Abd Ellah2; Sayed Ismail1
1Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt
2Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt Department of Pharmaceutics, Faculty of Pharmacy, Badr University in Assiut, Naser city, Assiut, Egypt
Abstract
Prevalence of nonalcoholic fatty liver disease (NAFLD) affects more than 25% of the populations worldwide. In this study, resveratrol loaded solid lipid nanoparticles (Res-SLNs) were prepared by emulsification and were in vitro evaluated. Res-SLN 1 containing gelucire and tween 80 was selected for further in vitro and in vivo studies. In vivo studies were done via induction of NAFLD in rats with a high fat (HF) diet for 12-weeks followed by a 6-week period of treatment with Res-SLN1. Blood samples and liver sections were taken from rats for biochemical and histological evaluations. Res-SLN1 exhibited high entrapment efficiency (75±22%), small particle size (208±48 nm) and an acceptable release rate. In vivo studies demonstrated a remarkable improvement in lipid profile and liver enzyme with Res-SLN1. The histological features were significantly improved with Res-SLN1. Res-SLNs represent a promising therapeutic approach for NAFLD via prolonging Res release and ameliorating lipid profile and liver enzymes.
Keywords
Nonalcoholic fatty liver disease; resveratrol; solid lipid nanoparticles
Statistics
Article View: 170
PDF Download: 225